Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS BLOOD ADV
METTL16-mediated inhibition of MXD4 promotes leukemia through activation of the MYC-MAX axis Oncogene
Corrigendum to "Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): Results from a population-based study" [Eur. J. Cancer 2025 Aug 26;226:115535. PMID: 40743655] Eur J Cancer
Impact of MICA-129 mismatch on HSCT outcomes: Evidence from a large European cohort and meta-analysis TRANSPL CELL THER
Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study Blood Adv
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial Lancet Haematol